GenVec Receives $2.5m Phase 2 SBIR Grant

GenVec, a bio-pharmaceutical company developing novel gene-based therapeutic drugs and vaccines, has received a phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant is intended to support the development of its vector production technology.

According to the company, funds from this grant, valued at approximately $2.5m over three years, will be used to support the development of novel cell lines capable of producing vaccine vectors, based on different human serotype groups and encoding inhibitory antigens.

Doug Brough, executive director of Vector Sciences at GenVec, said: This important grant will support work to advance our cell line technology and enhance GenVec’s ability to discover and develop new adenovector-based vaccines and therapeutics.